Speedel buy rating retained by Merrill

Merrill Lynch analyst Peter Welford retained Speedel Holdings at a buy rating on news that Novartis announced further positive phase 3 clinical trial data for SPP100, now called Rasilez, for hypertension. The company expects to file with the FDA early this year. Merrill believes that, marketed by Novartis, SPP100 global sales could reach about $1.5 billion five years after launch. Shares of the Basel, Switzerland, pharmaceutical company were up CHF3.40, or 2.46%, at CHF141.40 on volume of 21,584 shares versus the three-month running average of 4,005 shares. (Switzerland: SW)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.